

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:52:31 ON 05 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:52:39 ON 05 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2007 HIGHEST RN 919280-84-5

DICTIONARY FILE UPDATES: 4 FEB 2007 HIGHEST RN 919280-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10550663a.str



chain nodes :

10 11 12

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

16

chain bonds :

8-10 10-11 11-12 12-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

6-9 8-9 10-11 11-12 12-16

exact bonds :

5-7 7-8 8-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:Atom 12:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d lol

L1 HAS NO ANSWERS

'LO1 ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains  
data. (Default)

SIM ----- Structure Image.

SAT ----- Structure Attributes and map table if it contains data.


SCT ----- Structure Connection Table and map table if it contains  
data.

SDA ----- All Structure Data (image, attributes, connection table and  
map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIM), NOS:.

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:53:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 934 TO ITERATE

100.0% PROCESSED 934 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 16847 TO 20513

PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:53:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 19549 TO ITERATE

100.0% PROCESSED 19549 ITERATIONS

100 ANSWERS

SEARCH TIME: 00.00.01

L3 100 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 11:53:29 ON 05 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Feb 2007 VOL 146 ISS 7  
FILE LAST UPDATED: 4 Feb 2007 (20070204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857600 CAPLUS

DOCUMENT NUMBER: 141:332183

TITLE: Preparation of azaindole derivatives  
(pyrrolopyridines), preparations thereof, uses thereof  
and compositions containing them

INVENTOR(S): Wei, Zhongyong; Dolaine, Regis; Walpole, Christopher;  
Yang, Hua

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087704	A1	20041014	WO 2004-SE472	20040326
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1615922	A1	20060118	EP 2004-723882	20040326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006522112	T	20060928	JP 2006-507989	20040326



US 2007027179  
PRIORITY APPLN. INFO.:

A1 20070201  
MARPAT 141:332183

US 2005-550663  
SE 2003-908  
WO 2004-SE472

20050926  
A 20030331  
W 20040326

OTHER SOURCE(S):  
GI




AB Compds. of formula I [R1 = cycloalkylmethyl or tetrahydropyranylmethyl; X = divalent group that separates groups connected thereto by one or two saturated carbons; Ar = divalent aromatic group; R2 = (un)substituted-alkyl, -aryl or heteroaryl; R3 = carbon group connected to the six membered ring via a N atom or carbonyl group; Ra and Rb = R, halo, NO2, OR, CO2H, etc., wherein R = H or alkyl], as well as their pharmaceutically acceptable salts, and pharmaceutical compns. including the compds. are prepared Thus, e.g., II was prepared by substitution of 2-chloro-3-methyl-5-nitropyridine with cyclohexylmethylamine followed by nitro group reduction, amidation with trimethylacetyl chloride, and cyclocondensation with Me 4-ethoxybenzeneacetic acid ester. I possessed Ki values of 29-5852 nM in assays with human CB1 receptors. They are useful in therapy, in particular in the management of pain.

IT 773147-25-4P 773147-54-9P 773147-78-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of pyrrolopyridines with analgesic activity)


RN 773147-25-4 CAPLUS

CN Carbamic acid, [1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773147-54-9 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-78-7 CAPLUS

CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, 1-methylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-42-5


CMF C26 H34 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 773147-21-0P 773147-22-1P 773147-23-2P  
 773147-24-3P 773147-26-5P 773147-27-6P  
 773147-28-7P 773147-29-8P 773147-30-1P  
 773147-31-2P 773147-32-3P 773147-33-4P  
 773147-34-5P 773147-35-6P 773147-36-7P  
 773147-37-8P 773147-38-9P 773147-39-0P  
 773147-40-3P 773147-41-4P 773147-42-5P  
 773147-43-6P 773147-44-7P 773147-45-8P  
 773147-46-9P 773147-47-0P 773147-48-1P  
 773147-49-2P 773147-50-5P 773147-51-6P  
 773147-52-7P 773147-53-8P 773147-55-0P  
 773147-56-1P 773147-57-2P 773147-59-4P  
 773147-61-8P 773147-63-0P 773147-64-1P  
 773147-65-2P 773147-67-4P 773147-69-6P  
 773147-70-9P 773147-72-1P 773147-74-3P  
 773147-76-5P 773147-79-8P 773147-80-1P  
 773147-81-2P 773147-82-3P 773147-83-4P  
 773147-84-5P 773147-85-6P 773147-86-7P  
 773147-87-8P 773147-88-9P 773147-89-0P  
 773147-90-3P 773147-91-4P 773147-92-5P  
 773147-93-6P 773147-94-7P 773147-95-8P  
 773147-96-9P 773147-97-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of pyrrolopyridines with analgesic activity)


RN 773147-21-0 CAPLUS

CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-  
 b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 773147-22-1 CAPLUS

CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-  
 pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-23-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-24-3 CAPLUS

CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-26-5 CAPLUS


CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-27-6 CAPLUS




CN 2-Pyridinecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-28-7 CAPLUS

CN Butanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-29-8 CAPLUS

CN Urea, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 773147-30-1 CAPLUS

CN 1H-Imidazole-5-sulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,1-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-31-2 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-32-3 CAPLUS

CN Benzamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-(dimethylamino)-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-33-4 CAPLUS

CN Benzoic acid, 4-[[[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)




RN 773147-34-5 CAPLUS

CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-2-nitro- (9CI) (CA INDEX NAME)




RN 773147-35-6 CAPLUS

CN Benzenesulfonamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-36-7 CAPLUS

CN Cyclobutanecarboxamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-37-8 CAPLUS

CN Benzamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,5-difluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-38-9 CAPLUS

CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-39-0 CAPLUS

CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)




RN 773147-40-3 CAPLUS

CN Urea, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 773147-41-4 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-42-5 CAPLUS

CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 773147-43-6 CAPLUS

CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-44-7 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)




RN 773147-45-8 CAPLUS

CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-46-9 CAPLUS

CN Benzenesulfonamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-47-0 CAPLUS

CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 773147-48-1 CAPLUS

CN Urea, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 773147-49-2 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)




RN 773147-50-5 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-51-6 CAPLUS

CN Cyclopropanecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-52-7 CAPLUS

CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 773147-53-8 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-55-0 CAPLUS

CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl- (9CI) (CA INDEX NAME)







RN 773147-56-1 CAPLUS  
 CN Butanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-57-2 CAPLUS  
 CN Propanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 773147-59-4 CAPLUS  
 CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-61-8 CAPLUS  
 CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-53-8  
 CMF C27 H35 N3 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-63-0 CAPLUS  
CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 773147-21-0  
CMF C28 H38 N4 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 773147-64-1 CAPLUS  
CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-

pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 773147-22-1  
CMF C29 H39 N3 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-65-2 CAPLUS  
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)


CM 1

CRN 773147-50-5  
CMF C28 H37 N3 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-67-4 CAPLUS  
 CN Cyclopropanecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-51-6  
 CMF C28 H35 N3 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 773147-69-6 CAPLUS  
 CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 773147-49-2  
 CMF C29 H39 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-70-9 CAPLUS

CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N',N'-diethyl-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-43-6


CMF C29 H40 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-72-1 CAPLUS

CN 3-Isoxazolecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 773147-23-2

CMF C29 H34 N4 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-74-3 CAPLUS  
CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-55-0  
CMF C31 H34 F N3 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 773147-76-5 CAPLUS  
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI)

(CA INDEX NAME)

CM 1

CRN 773147-41-4


CMF C27 H36 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-79-8 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 773147-44-7


CMF C28 H38 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 773147-80-1 CAPLUS  
 CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)


CM 1

CRN 773147-45-8  
 CMF C28 H38 N4 O2



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 773147-81-2 CAPLUS  
 CN Urea, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 773147-48-1  
 CMF C27 H37 N5 O2





CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-82-3 CAPLUS  
CN Benzenesulfonamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-35-6  
CMF C29 H31 F2 N3 O4 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 773147-83-4 CAPLUS

CN Cyclobutanecarboxamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-36-7


CMF C28 H35 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-84-5 CAPLUS

CN Benzamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,5-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-37-8


CMF C30 H31 F2 N3 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 773147-85-6 CAPLUS  
 CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-38-9  
 CMF C27 H35 N3 O3



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 773147-86-7 CAPLUS  
 CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-39-0  
 CMF C28 H37 N3 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-87-8 CAPLUS  
CN Urea, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-40-3  
CMF C27 H36 N4 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 773147-88-9 CAPLUS

CN Butanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-56-1


CMF C28 H37 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-89-0 CAPLUS

CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-26-5


CMF C28 H29 F2 N3 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 773147-90-3 CAPLUS  
 CN 2-Pyridinecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)


CM 1

CRN 773147-27-6  
 CMF C28 H30 N4 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 773147-91-4 CAPLUS  
 CN Butanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 773147-28-7  
 CMF C27 H35 N3 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-92-5, CAPLUS

CN Urea, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI)  
(CA INDEX NAME)

CM 1

CRN 773147-29-8


CMF C26 H34 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 773147-93-6 CAPLUS  
 CN 1H-Imidazole-5-sulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,1-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-30-1  
 CMF C26 H31 N5 O3 S



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 773147-94-7 CAPLUS  
 CN 3-Isioxazolecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 773147-31-2  
 CMF C27 H30 N4 O3



CM 2




CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-95-8 CAPLUS  
CN Benzamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-(dimethylamino)-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 773147-32-3  
CMF C31 H36 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 773147-96-9 CAPLUS  
CN Benzoic acid, 4-[[[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 773147-33-4  
CMF C29 H31 N3 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 773147-97-0 CAPLUS

CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-2-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-34-5


CMF C28 H30 N4 O5 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2




IT 773148-01-9P 773148-02-0P 773148-06-4P  
 773148-07-5P 773148-08-6P 773148-10-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of pyrrolopyridines with analgesic activity)  
 RN 773148-01-9 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(4-  
 ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 773148-02-0 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(4-  
 ethoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773148-06-4 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(5-ethoxy-2-  
 pyridinyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 773148-07-5 CAPLUS  
 CN Carbamic acid, [2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-  
 yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX  
 NAME)




RN 773148-08-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 2-[(4-ethoxyphenyl)methyl]-N-methyl-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 773148-10-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:796483 CAPLUS

DOCUMENT NUMBER: 139:292139

TITLE: Preparation of heteroarylalkanols as glucocorticoid mimetics for treatment of inflammatory, allergic, and proliferative diseases

INVENTOR(S): Bekkali, Younes; Betageri, Raj; Gilmore, Thomas A.; Cardozo, Mario G.; Kirrane, Thomas M.; Kuzmich, Daniel; Proudfoot, John Robert; Takahashi, Hidenori; Thomson, David; Wang, Ji; Zindell, Renee; Harcken, Christian Hanke Justus Joachim; Riether, Doris

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA




SOURCE: PCT Int. Appl., 277 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082280	A1	20031009	WO 2003-US8901	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478156	A1	20031009	CA 2003-2478156	20030321
AU 2003218342	A1	20031013	AU 2003-218342	20030321
US 2004023999	A1	20040205	US 2003-394303	20030321
US 6903215	B2	20050607		
EP 1490062	A1	20041229	EP 2003-714339	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008784	A	20050111	BR 2003-8784	20030321
CN 1633296	A	20050629	CN 2003-807180	20030321
JP 2005527555	T	20050915	JP 2003-579818	20030321
NZ 535889	A	20060331	NZ 2003-535889	20030321
IN 2004DN02316	A	20050401	IN 2004-DN2316	20040810
US 2005059714	A1	20050317	US 2004-944615	20040917
NO 2004004031	A	20041019	NO 2004-4031	20040924
US 2005282881	A1	20051222	US 2005-185349	20050720
US 2006189647	A1	20060824	US 2006-410408	20060425
PRIORITY APPLN. INFO.:			US 2002-367758P	P 20020326
			US 2002-431817P	P 20021209
			US 2003-442404P	P 20030124
			US 2003-394303	A1 20030321
			WO 2003-US8901	W 20030321
			US 2004-944615	A1 20040917
			US 2005-185349	A1 20050720
OTHER SOURCE(S):		MARPAT 139:292139		
GI				




AB Title compds. I and II [wherein R1 = substituted (hetero)aryl; R2 and R3 = independently H or alkyl; or CR2R3 = cycloalkyl; R4 = (un)substituted alkyl, alkenyl, or alkynyl; R5 = substituted heteroaryl; and R6 (when present) = (un)substituted alkyl, alkenyl, alkynyl, carbocyclyl(alkyl), heterocyclyl(alkyl), (hetero)aryl(alkyl), arylhaloalkyl, carbocyclylalkenyl, heterocyclylalkenyl, or (hetero)arylalkenyl; and tautomers, prodrugs, solvates, or salts thereof] were prepared as glucocorticoid mimetics (no data). For example, 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-one (multi-step preparation from Et trifluoropyruvate, 1-bromo-2-methylpropene, and 4-fluoroanisole given) was coupled with 2-methyl-5-phenylbenzoxazole using LDA in THF to afford III. I, II, and pharmaceutical compns. containing such compds. are useful for treating inflammatory, allergic, or proliferative disorders mediated by glucocorticoid receptor (GR) function (no data).

IT 609851-47-0P, 1,1,1-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-[(1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]pentan-2-ol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (glucocorticoid mimetic; preparation of heteroarylalkanols as GR modulators for treatment of inflammatory, allergic, and proliferative diseases)

RN 609851-47-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-ethanol,  $\alpha$ -[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]- $\alpha$ -(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:356415 CAPLUS

DOCUMENT NUMBER: 138:368759

TITLE: Preparation of 2-acylindoles as tubulin polymerization inhibitors for the treatment of metastatic tumors

INVENTOR(S): Beckers, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Joerg; Vanhoefer, Udo

PATENT ASSIGNEE(S): Baxter Healthcare SA, Switz.

SOURCE: PCT Int. Appl., 110 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037861	A1	20030508	WO 2002-EP11883	20021024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				







RN 370580-90-8 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
 (CA INDEX NAME)



RN 370580-91-9 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)-  
 (9CI) (CA INDEX NAME)




RN 370580-92-0 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)-  
 (9CI) (CA INDEX NAME)




RN 521309-89-7 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)







RN 521309-90-0 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 521309-91-1 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-5-methoxy-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 521309-92-2 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 521310-04-3 CAPLUS  
 CN Methanone, (5-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl) (3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 521310-05-4 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-acetyl-5-methoxy-2-(3,4,5-trimethoxybenzoyl)-, 7-oxide (9CI) (CA INDEX NAME)




IT 370581-48-9P 370581-49-0P 370581-50-3P  
 370581-51-4P 521309-94-4P 521309-95-5P  
 521309-96-6P 521309-97-7P 521309-98-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of acylindoles as tubulin polymerization inhibitors for the treatment of metastatic tumors)


RN 370581-48-9 CAPLUS  
 CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-49-0 CAPLUS  
 CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-50-3 CAPLUS  
 CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 370581-51-4 CAPLUS  
 CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 521309-94-4 CAPLUS  
 CN Methanone, (2-methoxyphenyl) (5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 521309-95-5 CAPLUS  
 CN Methanone, (3-methoxyphenyl) (5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 521309-96-6 CAPLUS  
 CN Methanone, (2,4-dimethoxyphenyl) (5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 521309-97-7 CAPLUS  
 CN Methanone, (5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl) (3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 521309-98-8 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-acetyl-6-ethoxy-2-(3,4,5-trimethoxybenzoyl)-  
 (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:836852 CAPLUS

DOCUMENT NUMBER: 136:112229

TITLE: Synthetic 2-Aroylindole Derivatives as a New Class of  
 Potent Tubulin-Inhibitory, Antimitotic Agents  
 AUTHOR(S): Mahboobi, Siavosh; Pongratz, Herwig; Hufsky, Harald;  
 Hockemeyer, Joerg; Frieser, Markus; Lyssenko, Alexei;  
 Paper, Dietrich H.; Buergermeister, Jutta; Boehmer,  
 Frank-D.; Fiebig, Heinz-Herbert; Burger, Angelika M.;  
 Baasner, Silke; Beckers, Thomas

CORPORATE SOURCE: Faculty of Chemistry and Pharmacy Institute of  
 Pharmacy, University of Regensburg, Regensburg,  
 D-93040, Germany

SOURCE: Journal of Medicinal Chemistry (2001), 44(26),  
 4535-4553

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:112229

AB A new class of simple synthetic antimitotic compds. based on  
 2-aroylindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone  
 (I) as well as analogous 3-fluorophenyl- and 3-methoxyphenyl derivs.  
 displayed high cytotoxicity of IC<sub>50</sub> = 20 to 75 nM against the human  
 HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell  
 lines. The inhibition of proliferation correlated with the arrest in the  
 G2/M phase of the cell cycle. In in vitro assays with tubulin isolated  
 from bovine brain, in general antiproliferative activity correlated with  
 inhibition of tubulin polymerization. Thus, the antimitotic activity of  
 2-aroylindoles is explained by interference with the mitotic spindle apparatus  
 and destabilization of microtubules. In contrast to colchicine,  
 vincristine, nocodazole, or taxol, I did not significantly affect the  
 GTPase activity of  $\beta$ -tubulin. Interestingly, selected compds.  
 inhibited angiogenesis in the chorioallantoic membrane (CAM) assay. In  
 xenograft expts., I was highly active after oral administration at 200  
 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude

mice. We conclude, that 2-aryloindoles constitute an interesting new class of antitubulin agents with the potential to be clin. developed for cancer treatment.


IT 370581-48-9P 370581-49-0P 370581-50-3P  
370581-51-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloindoles as tubulin-inhibitory antimitotic agents)


RN 370581-48-9 CAPLUS

CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-49-0 CAPLUS

CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-50-3 CAPLUS

CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 370581-51-4 CAPLUS

CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




IT 370580-89-5P 370580-90-8P 370580-91-9P  
370580-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryloindoles as tubulin-inhibitory antimitotic agents)


RN 370580-89-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)




RN 370580-90-8 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)



RN 370580-91-9 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)-  
(9CI) (CA INDEX NAME)



RN 370580-92-0 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:816437 CAPLUS

DOCUMENT NUMBER: 135:352771

TITLE: (Hetero)indole derivatives, their preparation, pharmaceutical compositions, and their use as antitumor agents

INVENTOR(S): Beckers, Thomas; Baasner, Silke; Klenner, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Jorg; Fiebig, Heinz-Herbert; Burger, Angelika; Bohmer, Frank-D.

PATENT ASSIGNEE(S): Asta Medica A.-G., Germany

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082909	A2	20011108	WO 2001-EP4783	20010427
WO 2001082909	A3	20020314		
W: AT, AU, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DZ, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LU, LV, MK, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10020852	A1	20011031	DE 2000-10020852	20000428
DE 10102629	A1	20020725	DE 2001-10102629	20010120
CA 2407677	A1	20021028	CA 2001-2407677	20010427
EP 1276720	A2	20030122	EP 2001-947247	20010427
EP 1276720	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR				
BR 2001010414	A	20030211	BR 2001-10414	20010427
HU 200300480	A2	20030628	HU 2003-480	20010427
JP 2004501092	T	20040115	JP 2001-579784	20010427
EE 200200607	A	20040415	EE 2002-607	20010427
AU 783459	B2	20051027	AU 2001-68984	20010427
NZ 522246	A	20060127	NZ 2001-522246	20010427
NO 2002005150	A	20021216	NO 2002-5150	20021025
IN 2002KN01342	A	20050311	IN 2002-KN1342	20021028
BG 107309	A	20030930	BG 2002-107309	20021125
PRIORITY APPLN. INFO.:				
			DE 2000-10020852	A 20000428
			DE 2001-10102629	A 20010120
			WO 2001-EP4783	W 20010427

OTHER SOURCE(S): CASREACT 135:352771; MARPAT 135:352771

GI



AB The invention discloses indole and heteroindole derivs. I [R1 = H, C1-6 alkyl, C1-6 alkylcarbonyl, etc.; R2 = H, halo, cyano, etc.; R3-R6 = H, halo, nitro, etc.; A-D = C, N; Y = (un)substituted C6-14 aryl, etc.; X =

O, S, NH, CHOH], and tautomers, stereoisomers, mixts. and salts thereof, as well as the production thereof and the use thereof for the treatment of tumors.


IT 370580-89-5P 370580-90-8P 370580-91-9P  
370580-92-0P 370581-50-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(indole and heteroindole derivs. for antitumor agents, preparation, and pharmaceutical comps.)


RN 370580-89-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)




RN 370580-90-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)



RN 370580-91-9 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 370580-92-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)







RN 370581-50-3 CAPLUS  
 CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl (3,4,5-trimethoxyphenyl)- (9CI)  
 (CA INDEX NAME)




IT 370581-48-9P 370581-49-0P 370581-51-4P  
 370581-56-9P 370581-58-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (indole and heteroindole derivs. for antitumor agents, preparation, and  
 pharmaceutical compns.)  
 RN 370581-48-9 CAPLUS  
 CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA  
 INDEX NAME)




RN 370581-49-0 CAPLUS  
 CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA  
 INDEX NAME)




RN 370581-51-4 CAPLUS  
 CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA  
 INDEX NAME)



RN 370581-56-9 CAPLUS  
 CN Methanone, (7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl) (3,4,5-trimethoxyphenyl)-  
 (9CI) (CA INDEX NAME)



RN 370581-58-1 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 1-acetyl-2-(3,4,5-trimethoxybenzoyl)-,  
 acetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:795073 CAPLUS  
 DOCUMENT NUMBER: 135:331343  
 TITLE: Preparation of 1H-indol-2-yl aryl ketones and related  
 compounds as antitumor agents  
 INVENTOR(S): Beckers, Thomas; Baasner, Silke; Klenner, Thomas;  
 Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus;  
 Hufsky, Harald; Hockemeyer, Joerg; Fiebig,  
 Heinz-Herbert; Burger, Angelika; Boehmer, Frank-D.  
 PATENT ASSIGNEE(S): Asta Medica A.-G., Germany  
 SOURCE: Ger. Offen., 34 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10020852	A1	20011031	DE 2000-10020852	20000428
WO 2001082909	A2	20011108	WO 2001-EP4783	20010427
WO 2001082909	A3	20020314		

W: AT, AU, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DZ, EE, ES, FI,  
 GB, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LU, LV, MK,  
 MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, US, UZ, YU,  
 ZA, AM, AZ, MD, TJ, TM  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE, TR

US 2002091124	A1	20020711	US 2001-843139	20010427
CA 2407677	A1	20021028	CA 2001-2407677	20010427
EP 1276720	A2	20030122	EP 2001-947247	20010427
EP 1276720	B1	20061220		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR


BR 2001010414	A	20030211	BR 2001-10414	20010427
HU 200300480	A2	20030628	HU 2003-480	20010427
JP 2004501092	T	20040115	JP 2001-579784	20010427
EE 200200607	A	20040415	EE 2002-607	20010427
AU 783459	B2	20051027	AU 2001-68984	20010427
NZ 522246	A	20060127	NZ 2001-522246	20010427
US 2003158216	A1	20030821	US 2002-279123	20021024
NO 2002005150	A	20021216	NO 2002-5150	20021025
IN 2002KN01342	A	20050311	IN 2002-KN1342	20021028
ZA 2002009137	A	20040618	ZA 2002-9137	20021111
BG 107309	A	20030930	BG 2002-107309	20021125

PRIORITY APPLN. INFO.:

DE 2000-10020852	A	20000428
DE 2001-10102629	A	20010120
US 2001-843139	B1	20010427
WO 2001-EP4783	W	20010427

OTHER SOURCE(S): MARPAT 135:331343

GI



AB Use of title compds. [I; R1 = H, alkylcarbonyl, alkylaminoalkyl, dialkylaminoalkyl, (hetero)cyclyl; R2 = H, halo, cyano, NO<sub>2</sub>, (substituted) alkyl, alkoxy, etc.; A-D = N, (substituted) C; R3-R6 = free electron pair if A-D = N, or H, halo, cyano, NO<sub>2</sub>, alkyl, etc. if A-D = C; Y = (substituted) aryl; X = O, S, NH, (H,OH)], for preparation of drugs for treatment of tumor illness in mammals is claimed. Thus, 5-methoxy-1H-indol-2-yl Ph ketone (general preparation given) showed antitumor activity with IC<sub>50</sub> = 96.5 nM in rat glioma cell lines C6.

IT 370581-50-3P, (1H-Pyrrolo[2,3-b]pyridin-2-yl) (3,4,5-trimethoxyphenyl)methanone 370581-56-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of indolyl aryl ketones and related compds. as antitumor agents)

RN 370581-50-3 CAPLUS


CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl (3,4,5-trimethoxyphenyl)- (9CI)

(CA INDEX NAME)



RN 370581-56-9 CAPLUS

CN Methanone, (7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl) (3,4,5-trimethoxyphenyl)-  
(9CI) (CA INDEX NAME)




IT 370581-48-9P, (1H-Pyrrolo[2,3-b]pyridin-2-yl) (2-methoxyphenyl)methanone 370581-49-0P, (1H-Pyrrolo[2,3-b]pyridin-2-yl) (3-methoxyphenyl)methanone 370581-51-4P, (1H-Pyrrolo[2,3-b]pyridin-2-yl) (2,4-dimethoxyphenyl)methanone 370581-58-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of indolyl aryl ketones and related compds. as antitumor agents)


RN 370581-48-9 CAPLUS

CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-49-0 CAPLUS

CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)




RN 370581-51-4 CAPLUS

CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-58-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 1-acetyl-2-(3,4,5-trimethoxybenzoyl)-, acetate (ester) (9CI) (CA INDEX NAME)



IT 370580-89-5P 370580-90-8P 370580-91-9P


370580-92-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indolyl aryl ketones and related compds. as antitumor agents)


RN 370580-89-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)




RN 370580-90-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)



RN 370580-91-9 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 370580-92-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)-

(9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1997:198231 CAPLUS  
DOCUMENT NUMBER: 126:293275  
TITLE: Synthesis of 2-substituted-1H-pyrrolo[2,3-b]pyridines:  
preparation of 7-azaolivacine analog and  
7-azaindolopyridopyrimidine derivatives  
AUTHOR(S): Desarbres, Eric; Coudret, Sandrine; Meheust, Cecile;  
Merour, Jean-Yves  
CORPORATE SOURCE: Inst. Chimie Organique Analytique, Univ. d'Orleans,  
Orleans, F-45067, Fr.  
SOURCE: Tetrahedron (1997), 53(10), 3637-3648  
CODEN: TETRAB; ISSN: 0040-4020  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB 2-Substituted-1H-pyrrolo[2,3-b]pyridines I (R = Me, 4-MeC6H4CHOH,  
4-ClC6H4CHOH, etc.) have been prepared from 7-azaindole by lithiation  
followed by addition of various electrophiles. A 7-azaolivacine analog II  
and a pyrido[3',2':4,5]pyrrolo[1,2-c]pyrido[3,2-d]pyrimidine III have also  
been prepared  
IT 189089-95-0P 189089-96-1P 189089-97-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of pyrrolopyridines, azaolivacine analog, and  
azaindolopyridopyrimidine derivative)  
RN 189089-95-0 CAPLUS

CN 3-Pyridinecarboxamide, N,N-diethyl-4-[hydroxy[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 189089-96-1 CAPLUS

CN 3-Pyridinecarboxamide, N,N-diethyl-2-methoxy-4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 189089-97-2 CAPLUS

CN 3-Pyridinecarboxamide, N,N-diethyl-4-[1-hydroxy-1-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




IT 189089-84-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrrolopyridines, azaolivacine analog, and  
azaindolopyridopyrimidine derivative)

RN 189089-84-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-methanol, α-(4-methoxyphenyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
37.83	210.14

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.46	-5.46

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:54:53 ON 05 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 2, 2007 (20070202/UP).

=> d his

(FILE 'HOME' ENTERED AT 11:52:31 ON 05 FEB 2007)

FILE 'REGISTRY' ENTERED AT 11:52:39 ON 05 FEB 2007

L1 STRUCTURE UPLOADED  
L2 6 S L1  
L3 100 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:53:29 ON 05 FEB 2007

L4 7 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 11:54:53 ON 05 FEB 2007

=> log y  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.30	210.44

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-5.46

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:57:44 ON 05 FEB 2007